LBLTF (Lattice Biologics) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2021)


What is Lattice Biologics LT-Debt-to-Total-Asset?

Lattice Biologics LBLTF -99.00% LT-Debt-to-Total-Asset is 0.00 as of Jun. 2021.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lattice Biologics's long-term debt to total assests ratio for the quarter that ended in Jun. 2021 was 0.00.

Lattice Biologics's long-term debt to total assets ratio declined from Jun. 2020 (0.22) to Jun. 2021 (0.00). It may suggest that Lattice Biologics is progressively becoming less dependent on debt to grow their business.

Lattice Biologics  (OTCPK:LBLTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lattice Biologics LT-Debt-to-Total-Asset Related Terms

Lattice Biologics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics LT-Debt-to-Total-Asset Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.14 0.23 0.09 0.29

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.29 0.30 0.00 0.00

Lattice Biologics LT-Debt-to-Total-Asset Calculation

Lattice Biologics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2020 is calculated as

LT Debt to Total Assets (A: Sep. 2020 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2020 )/Total Assets (A: Sep. 2020 )
=0.888/3.018
=0.29

Lattice Biologics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2021 is calculated as

LT Debt to Total Assets (Q: Jun. 2021 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2021 )/Total Assets (Q: Jun. 2021 )
=0/0.606
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Lattice Biologics (LBLTF) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2021. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' LT-Debt-to-Total-Asset too high?
Lattice Biologics' current LT-Debt-to-Total-Asset is 0.00.
How does Lattice Biologics' LT-Debt-to-Total-Asset compare to ABT and MDT?
Lattice Biologics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lattice Biologics and its competitors. Lattice Biologics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.